Information Provided By: 
Fly News Breaks for October 20, 2016
GILD
Oct 20, 2016 | 10:50 EDT
Piper Jaffray analyst Joshua Schimmer says Gilead Sciences' Phase II results for GS-447 in nonalcoholic steatohepatitis are "limited and highly inconclusive" since the study did not include appropriate scale or placebo control. The results are "from compelling and well short of the bar we would like to see to advance" into Phase III, Schimmer tells investors in a research note. The analyst has an Overweight rating on the shares.
News For GILD From the Last 2 Days
There are no results for your query GILD
